Multi-Envelope HIV-1 Vaccine Development: Two Targeted Immune Pathways, One Desired Protective Outcome.


Journal Article (Review)

In 2016, there were more than 30 million individuals living with HIV-1, ∼1.8 million new HIV-1 infections, and ∼1 million HIV-1-related deaths according to UNAIDS ( ). Hence, a preventive HIV-1 vaccine remains a global priority. The variant envelopes of HIV-1 present a significant obstacle to vaccine development and the vaccine field has realized that immunization with a single HIV-1 envelope protein will not be sufficient to generate broadly neutralizing antibodies. Here we describe two nonmutually exclusive, targeted pathways with which a multi-envelope HIV-1 vaccine may generate protective immune responses against variant HIV-1. Pathways include (i) the induction of a polyclonal immune response, comprising a plethora of antibodies with subset-reactive and cross-reactive specificities, together able to neutralize diverse HIV-1 (termed Poly-nAb in this report) and (ii) the induction of one or a few monoclonal antibodies, each with a broadly neutralizing specificity (bnAb). With each pathway in mind, we describe challenges and strategies that may ultimately support HIV-1 vaccine success.

Full Text

Duke Authors

Cited Authors

  • Hurwitz, JL; Bonsignori, M

Published Date

  • March 2018

Published In

Volume / Issue

  • 31 / 2

Start / End Page

  • 124 - 132

PubMed ID

  • 29315059

Pubmed Central ID

  • 29315059

Electronic International Standard Serial Number (EISSN)

  • 1557-8976

Digital Object Identifier (DOI)

  • 10.1089/vim.2017.0144


  • eng

Conference Location

  • United States